Notably, a clinical trial in EoE found that an anti–IL–13 antibody could restore epithelial E‐cadherin and reduce vimentin‐positive cells, effectively reversing EMT biomarkers in the esophageal lining [172]. This evidence concerns the gene IL13 and eosinophilic esophagitis.